Summary
0.49 0.01(2.19%)09/16/2024
Novabay Pharmaceuticals Inc (NBY)
Novabay Pharmaceuticals Inc (NBY)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.19 | 6.53 | 0.76 | -81.87 | 232.10 | -5.10 | -8.67 | -99.48 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.49 | |
| Open | 0.50 | |
| High | 0.50 | |
| Low | 0.47 | |
| Volume | 6,855 | |
| Change | 0.01 | |
| Change % | 2.19 | |
| Avg Volume (20 Days) | 72,724 | |
| Volume/Avg Volume (20 Days) Ratio | 0.09 | |
| 52 Week Range | 0.07 - 3.55 | |
| Price vs 52 Week High | -86.33% | |
| Price vs 52 Week Low | 593.29% | |
| Range | -4.98 | |
| Gap Up/Down | 0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2 | |
| EBIDTA | -4,800,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 2.60 | |
| Book Value | 0.1210 | |
| Earnings Per Share | -3.9600 | |
| EPS Estimate Current Quarter | -0.1500 | |
| EPS Estimate Next Quarter | -0.0900 | |
| EPS Estimate Current Year | -0.2700 | |
| EPS Estimate Next Year | 0.0200 | |
| Diluted EPS (TTM) | -3.9600 | |
| Revenues | ||
| Profit Marging | -0.6546 | |
| Operating Marging (TTM) | -0.2141 | |
| Return on asset (TTM) | -0.2459 | |
| Return on equity (TTM) | -1.3903 | |
| Revenue TTM | 14,726,000 | |
| Revenue per share TTM | 3.4940 | |
| Quarterly Revenue Growth (YOY) | 0.0230 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 5,645,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.9948 | |
| Revenue Enterprise Value | 0.2907 | |
| EBITDA Enterprise Value | -0.8918 | |
| Shares | ||
| Shares Outstanding | 36,060,800 | |
| Shares Float | 29,955,786 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.03 | |
| Institutions (%) | 3.30 | |
08/13 23:29 EST - seekingalpha.com
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
NovaBay Pharmaceuticals, Inc. (NBY) Q2 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
08/13 16:05 EST - businesswire.com
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2024 and provides a business update. “Revenue growth was driven by higher Avenova sales through online channels including an expanded subscription customer base,” said Justin Hall, CEO of NovaBay. “The number of Subscribe & Save customers on Amazon.com increased 16% during the first half of the year. In fact, subscriber sales on Amazo.
NovaBay Pharmaceuticals Reports Second Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and six months ended June 30, 2024 and provides a business update. “Revenue growth was driven by higher Avenova sales through online channels including an expanded subscription customer base,” said Justin Hall, CEO of NovaBay. “The number of Subscribe & Save customers on Amazon.com increased 16% during the first half of the year. In fact, subscriber sales on Amazo.
07/16 06:50 EST - businesswire.com
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024. “Prime Day has been a highly productive event for NovaBay in past years and conveniently falls during National Dry Eye Awareness Month when there is increasing focus on this chronic condition that affects about 25 million Americans,” said Justin Hall, NovaBay CEO. “The discoun.
NovaBay Pharmaceuticals Offers 20% Discounts on Avenova Eyecare Products During Amazon Prime Day
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces 20% discounts on Avenova®-branded eyecare products and product bundles during Amazon Prime Day being held July 16-17, 2024. “Prime Day has been a highly productive event for NovaBay in past years and conveniently falls during National Dry Eye Awareness Month when there is increasing focus on this chronic condition that affects about 25 million Americans,” said Justin Hall, NovaBay CEO. “The discoun.
07/11 06:50 EST - businesswire.com
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) announces preliminary net revenue for the second quarter of 2024 of $2.4 million and for the first half of 2024 of $5.0 million, primarily derived from the Company's eyecare products. Net revenue from the Company's eyecare products increased by 9% for both the second quarter and the first half of 2024 over the corresponding periods in 2023. NovaBay also expects 2024 net revenue f.
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue of $2.4 Million
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company” or “NovaBay”) announces preliminary net revenue for the second quarter of 2024 of $2.4 million and for the first half of 2024 of $5.0 million, primarily derived from the Company's eyecare products. Net revenue from the Company's eyecare products increased by 9% for both the second quarter and the first half of 2024 over the corresponding periods in 2023. NovaBay also expects 2024 net revenue f.
06/28 06:50 EST - businesswire.com
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye Awareness Month is intended to recognize the importance of eye health to overall health, and to educate the public about dry eye. The Sjögren's Foundation and its partners first asked Con.
NovaBay Pharmaceuticals Supports National Dry Eye Awareness Month with Multiple Avenova Product Promotions
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye Awareness Month is intended to recognize the importance of eye health to overall health, and to educate the public about dry eye. The Sjögren's Foundation and its partners first asked Con.
06/07 06:50 EST - businesswire.com
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company's plan to regain compliance with NYSE American's continued listing standards. “I'm pleased to report on our forward momentum. By divesting an unprofitable business segment earlier this year, we're now able to focus solely on our core competency in eyecare,” said Justin Hall, CEO of NovaBay. “Unshackled by past bu.
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) (the “Company”) announces that the NYSE American LLC (“NYSE American”) has accepted the Company's plan to regain compliance with NYSE American's continued listing standards. “I'm pleased to report on our forward momentum. By divesting an unprofitable business segment earlier this year, we're now able to focus solely on our core competency in eyecare,” said Justin Hall, CEO of NovaBay. “Unshackled by past bu.
05/30 08:41 EST - investorplace.com
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?
NovaBay Pharmaceuticals (NYSEMKT: NBY ) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split.
Why Is NovaBay Pharmaceuticals (NBY) Stock Down 39% Today?
NovaBay Pharmaceuticals (NYSEMKT: NBY ) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split.
05/29 17:22 EST - businesswire.com
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company's Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission (the “SEC”) were approved by stockholders at its 2024 Annual Meeting of Stockholders held on May 28, 2024. Among the proposals, stockholders approved a reverse stock split and authorized the Company's Board of Directors to d.
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. the “Company”) (NYSE American: NBY) announces that a quorum was reached and that all proposals in the Company's Definitive Proxy Statement filed on April 18, 2024 with the Securities and Exchange Commission (the “SEC”) were approved by stockholders at its 2024 Annual Meeting of Stockholders held on May 28, 2024. Among the proposals, stockholders approved a reverse stock split and authorized the Company's Board of Directors to d.
05/21 09:51 EST - zacks.com
NovaBay Pharmaceuticals (NBY) Shows Fast-paced Momentum But Is Still a Bargain Stock
NovaBay Pharmaceuticals (NBY) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
NovaBay Pharmaceuticals (NBY) Shows Fast-paced Momentum But Is Still a Bargain Stock
NovaBay Pharmaceuticals (NBY) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
05/13 08:30 EST - businesswire.com
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova® product bundles specifically designed to provide easy, affordable and effective solutions for individualized relief from dry eye symptoms. The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report o.
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces the introduction of an expanded line of Avenova® product bundles specifically designed to provide easy, affordable and effective solutions for individualized relief from dry eye symptoms. The new Avenova product bundles align with findings among optometrists surveyed in the Eyes on Eyecare 2024 Dry Eye Report o.
05/11 13:59 EST - seekingalpha.com
NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Bruce Voss - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Ladies and gentlemen, welcome to the NovaBay Pharmaceuticals Financial Results Conference Call. At this time, all participants are in a listen-only mode.
NovaBay Pharmaceuticals, Inc. (NBY) Q1 2024 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Bruce Voss - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Ladies and gentlemen, welcome to the NovaBay Pharmaceuticals Financial Results Conference Call. At this time, all participants are in a listen-only mode.
05/09 16:05 EST - businesswire.com
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. “Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online channels and by sales of branded wound care products,” said Justin Hall, CEO of NovaBay. “During the quarter, ordered sales for Avenova products on Amazon.com, our most important sales.
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. “Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online channels and by sales of branded wound care products,” said Justin Hall, CEO of NovaBay. “During the quarter, ordered sales for Avenova products on Amazon.com, our most important sales.
05/07 08:00 EST - businesswire.com
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company's largest sales channel. Sales through Amazon for April 2024 increased by more than 20% compared with April 2023. “We are very excited about our progress with ordered product sales for Aven.
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces record ordered product sales during the month of April for its Avenova-branded eyecare products on Amazon.com, the Company's largest sales channel. Sales through Amazon for April 2024 increased by more than 20% compared with April 2023. “We are very excited about our progress with ordered product sales for Aven.
05/03 06:50 EST - businesswire.com
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emai.
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emai.
04/22 06:57 EST - businesswire.com
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products. The new and enhanced programs build upon the Company's past highly productive marketing.
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products. The new and enhanced programs build upon the Company's past highly productive marketing.
04/19 18:00 EST - businesswire.com
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with th.
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity. The Company must submit a plan by May 18, 2024 advising of actions it has taken or will take to regain compliance with th.
04/17 06:59 EST - businesswire.com
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company's lead product, Avenova Antimicrobial Lid & Lash Solution. “We started.
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023. This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company's lead product, Avenova Antimicrobial Lid & Lash Solution. “We started.
03/26 18:43 EST - seekingalpha.com
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript
NovaBay Pharmaceuticals, Inc. (NBY) Q4 2023 Earnings Call Transcript
03/26 16:05 EST - businesswire.com
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update. “Quarterly revenue from our eyecare and wound care segment increased 10% versus the prior year, driven by higher Avenova sales through our physician dispensed and OTC channels, and by higher sales of our branded wound care products,” said Justin Hall, CEO of NovaBay. “Last year we expanded our loyal.
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update. “Quarterly revenue from our eyecare and wound care segment increased 10% versus the prior year, driven by higher Avenova sales through our physician dispensed and OTC channels, and by higher sales of our branded wound care products,” said Justin Hall, CEO of NovaBay. “Last year we expanded our loyal.
03/25 18:38 EST - businesswire.com
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers.
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers.